U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
This article was originally published in PharmAsia News
Executive Summary
FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2